Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2012 - 2020)

Agios Pharmaceuticals (AGIO) has 9 years of Non-Current Deffered Revenue data on file, last reported at $491000.0 in Q2 2020.

• Quarterly Non-Current Deffered Revenue fell 99.05% year-over-year to $491000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $491000.0 (down 99.05% YoY) and the FY2019 annual result came in at $50.6 million, down 15.43% from the prior year.
• Non-Current Deffered Revenue slipped to $491000.0 in Q2 2020, from $571000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $183.5 million in Q2 2016 to a low of $491000.0 in Q2 2020.
• A 5-year average of $87.2 million and a median of $69.4 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue surged 1074.21% — and 2020, when it tumbled 99.05%.
• Tracing AGIO's Non-Current Deffered Revenue over 5 years: stood at $154.3 million in 2016, then decreased by 18.47% to $125.8 million in 2017, then sank by 52.46% to $59.8 million in 2018, then slipped by 15.43% to $50.6 million in 2019, then sank by 99.03% to $491000.0 in 2020.
• The last three Non-Current Deffered Revenue figures came in at $491000.0 (Q2 2020), $571000.0 (Q1 2020), and $50.6 million (Q4 2019), per Business Quant data.